Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05377372 · ClinicalTrials.gov registry record · NA

Early Life Exposures Among Children With Sickle Cell Disease

A NA study of Sickle Cell Disease and Breastfeeding, sponsored by University of Alabama at Birmingham.

Recruiting
Registry status
NA
Development phase
20
Enrollment target
1
Study location

NCT05377372 is a NA study of Sickle Cell Disease and Breastfeeding that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 20 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05377372, a NA study of Sickle Cell Disease and Breastfeeding, is actively recruiting participants, sponsored by University of Alabama at Birmingham.

RECRUITING
Registry status
NA
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

This study is being conducted to determine the relationship between early childhood exposures, such as Adverse Childhood Experiences, Social Determinants of Health and nutrition/breastfeeding, among children with sickle cell disease, and behavioral interventions aimed to reshape psychological resilience and lifestyle factors towards positive health outcomes.

Interventions

  • OTHER Observation
  • BEHAVIORAL Breastfeeding support group

Study Locations (1)

Alabama

  • University of Alabama at Birmingham - Birmingham

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2026-02-01
Est. Completion 2027-12-31
Phase NA

Sponsor

University of Alabama at Birmingham

1,160 total trials

What the Registry Record Tells You About NCT05377372

The ClinicalTrials.gov registry entry for NCT05377372 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (93% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 2 interventions - of which Observation is the first listed.

NCT05377372 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.

Frequently Asked Questions

What is clinical trial NCT05377372 about?

NCT05377372 is a clinical study titled "Early Life Exposures Among Children With Sickle Cell Disease". This study is being conducted to determine the relationship between early childhood exposures, such as Adverse Childhood Experiences, Social Determinants of Health and nutrition/breastfeeding, among children with sickle cell disease, and behavioral interventions aimed to reshape psychological resili...

What is the current status of trial NCT05377372?

This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2026-02-01. Estimated completion is 2027-12-31.

What conditions does trial NCT05377372 study?

This clinical trial studies the following conditions: Sickle Cell Disease, Breastfeeding, Adverse Childhood Experiences.

What interventions are being tested in trial NCT05377372?

The interventions under investigation include: Observation (OTHER), Breastfeeding support group (BEHAVIORAL).

Who is sponsoring clinical trial NCT05377372?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05377372 being conducted?

This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sickle Cell Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.